Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Science Applications International ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Kimberly-Clark (NYSE:KMB) from Buy to Hold.

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD ...